Journal Article

Neurocognitive, academic and functional outcomes in survivors of infant ependymoma (UKCCSG CNS 9204)

Grundy, Richard, Reed-Berendt, Rosa, Siddell, Poppy, Stocks, Helen, Morrall, Matthew C. H. J., Picton, Susan, Houston, Alexandra L., Moss, Kate

2019

Overview

Purpose This is the first UK multi-centre case-controlled study with follow-up in excess of 10 years to report the neurocognitive, academic and psychological outcomes of individuals diagnosed with a brain tumour in early childhood. Children enrolled into the UKCCSG CNS 9204 trial, diagnosed with intracranial ependymoma when aged ≤ 36 months old, who received a primary chemotherapy strategy to defer or avoid radiotherapy, were recruited. Methods Outcomes of those who relapsed and subsequently received radiotherapy ( n  = 13) were compared to those enrolled who did not relapse ( n  = 16), age-matched controls—diagnosed with solid non-central nervous system (SN-CNS; n  = 15) tumours or low-grade posterior fossa pilocytic astrocytoma (PFPA; n  = 15), and normative data. Analyses compared nine neurocognitive outcomes as primary measures with quality of survival as secondary measures. Results Relapsed ependymoma participants performed significantly worse than their non-relapsed counterparts on measures of Full Scale IQ, Perceptual Reasoning, Word Reading and Numerical Operations. The relapsed ependymoma group performed significantly worse than SN-CNS controls on all primary measures, whereas non-relapsing participants only differed significantly from SN-CNS controls on measures of Processing Speed and General Memory. Relapsed ependymoma participants fared worse than all groups on measures of quality of survival. Conclusions The relapsed irradiated ependymoma group demonstrated the most significantly impaired neurocognitive outcomes at long-term follow-up. Non-relapsing participants demonstrated better outcomes than those who relapsed. Results tentatively suggest avoiding radiotherapy helped preserve neurocognitive and learning outcomes of individuals diagnosed with ependymoma when aged ≤ 36 months old. Prospective neurocognitive surveillance is required. Recommendations for clinical and research practice are provided.

• Publisher: Springer Berlin Heidelberg,Springer Nature B.V
• Subject: Age / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Brain cancer / Brain Neoplasms - therapy / Cancer Survivors - statistics & numerical data / Case-Control Studies / Chemotherapy / Child Development - drug effects / Child Development - radiation effects / Child, Preschool / Ependymoma - therapy / Female / Gender / Humans / Infant / Infant, Newborn / Internet resources / Male / Medicine / Medicine & Public Health / Neoplasm Recurrence, Local - radiotherapy / Nervous system / Neurocognitive Disorders - etiology / Neurosciences / Neurosurgery / Original Article / Pediatrics / Radiation therapy / Radiotherapy - adverse effects / Radiotherapy - methods / Recovery of Function - drug effects / Recovery of Function - radiation effects / Tumors / United Kingdom